THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.20] ID: TIP-MED-000252

Timolol Maleate Ophthalmic (0.5% Glaucoma Beta-Blocker Drops)

Active Ingredient / Scientific Identity: Timolol Maleate Ophthalmic • Class: Non-Selective Beta-1 / Beta-2 Adrenergic Antagonist Ophthalmic Solution (Aqueous Humour Suppressant)

⚖️ Compare Profile
Generic / Entity NameTimolol Maleate Ophthalmic (0.5% Glaucoma Beta-Blocker Drops) ([12.20])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassNon-Selective Beta-1 / Beta-2 Adrenergic Antagonist Ophthalmic Solution (Aqueous Humour Su
Available Dosage FormsOphthalmic Solution (Eye Drops): 0.25% w/v, 0.5% w/v (5 mL vial); Gel-Forming Solution (GFS): 0.5% OD.
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: No ophthalmic dose adjustment required. • Hepatic: No ophthalmic dose adjustment required.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Timolol Maleate Ophthalmic (0.5% Glaucoma Beta-Blocker Drops) (TIP-MED-000252, Reference Code [12.20]) is classified under Ophthalmological & Otic (ENT) Preparations (Ch 12) as a Non-Selective Beta-1 / Beta-2 Adrenergic Antagonist Ophthalmic Solution (Aqueous Humour Suppressant). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.20], p. 164): Iopar, Glucomol, Timolet, Ocudor — Strengths & Dosage Forms: Ophthalmic Solution (Eye Drops): 0.25% w/v, 0.5% w/v (5 mL vial); Gel-Forming Solution (GFS): 0.5% OD.
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.20], p. 164): Iopar, Glucomol, Timolet, Ocudor — Strengths & Dosage Forms: Ophthalmic Solution (Eye Drops): 0.25% w/v, 0.5% w/v (5 mL vial); Gel-Forming Solution (GFS): 0.5% OD.
Dosage Forms & Available Strengths:
Ophthalmic Solution (Eye Drops): 0.25% w/v, 0.5% w/v (5 mL vial); Gel-Forming Solution (GFS): 0.5% OD.
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Blocks beta-2 adrenergic receptors on the non-pigmented ciliary epithelium -> decreases aqueous humour production by 30-50% -> lowers intraocular pressure (IOP) without affecting pupil size or accommodation.

4. Therapeutic Indications & Evidence-Supported Uses

  • Chronic open-angle glaucoma
  • ocular hypertension
  • secondary glaucoma

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adult: 1 drop of 0.25% or 0.5% solution into affected eye(s) twice daily (q12h); Gel-Forming Solution: 1 drop once daily in the morning. • Paediatric: Congenital/Paediatric Glaucoma: 0.25% 1 drop BD under specialist supervision (punctal occlusion mandatory).

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: No ophthalmic dose adjustment required. • Hepatic: No ophthalmic dose adjustment required.
Elimination & Renal Adjustment:
Renal: No ophthalmic dose adjustment required. • Hepatic: No ophthalmic dose adjustment required.
Hepatic Impairment Considerations:
Renal: No ophthalmic dose adjustment required. • Hepatic: No ophthalmic dose adjustment required.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindications: Bronchial asthma or history of asthma, severe COPD, sinus bradycardia (<50 bpm), 2nd- or 3rd-degree AV block, overt cardiac failure, cardiogenic shock. • Precautions: CRITICAL SYSTEMIC ABSORPTION HAZARD: Eye drops draining through the nasolacrimal duct into the nasal mucosa bypass hepatic first-pass metabolism—1 drop of 0.5% Timolol in each eye delivers systemic beta-blockade equivalent to a 10 mg oral dose and can trigger fatal bronchospasm in asthmatics or complete heart block in the elderly!

Key Clinical Precautions: Renal: No ophthalmic dose adjustment required. • Hepatic: No ophthalmic dose adjustment required.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Transient ocular burning/stinging, dry eyes, blurred vision (gel).
  • Severe bronchospasm/status asthmaticus, sinus bradycardia, syncope, heart block, masking of hypoglycaemia in insulin-treated diabetics.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Oral Beta-blockers (Metoprolol, Bisoprolol), Verapamil, Diltiazem, Digoxin, Amiodarone -> additive severe bradycardia, AV block, and hypotension; Inhalational Beta-2 agonists (Salbutamol) -> antagonises bronchodilation

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: MANDATORY NASOLACRIMAL OCCLUSION TECHNIQUE: After instilling 1 drop, close eyelids gently and press index finger firmly over the inner corner of the eye (tear duct next to nose) for 2 full minutes—this cuts systemic bloodstream absorption by >65% and improves eye efficacy; wait >=5 minutes between different eye drops.
  • Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
  • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
  • Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Ophthalmic Solution (Eye Drops): 0.25% w/v, 0.5% w/v (5 mL vial); Gel-Forming Solution (GFS): 0.5% OD.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.20] (p. 164)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.